Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. USO
6. MU
7. HOOD
8. DFTX
9. GOOGL
10. ABBV

Go back to Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Deutsche Bank

July 23, 2024 6:35 AM EDT

Deutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $45.00 (from $53.00) while maintaining a Hold rating.

The analyst comments "IQVIA script (TRx) data point to BMY 2Q24 Revs of ~$11.6B to nudge ahead of BBG cons. of ~$11.5B, though non-GAAP EPS of... More